Meghana Ajay Deshpande
Meghana Ajay Deshpande has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Nilesh Rathi
Department of Pediatric and Preventive Dentistry Sharad Pawar Dental College Datta Meghe Institute of Medical Sciences Wardha Maharashtra India
2 shared publicationsNilima Thosar
Department of Pediatric and Preventive Dentistry Sharad Pawar Dental College Datta Meghe Institute of Medical Sciences Wardha Maharashtra India
2 shared publications- Nilima Thosar
Department of Pediatric and Preventive Dentistry, Sharad Pawar Dental College and Hospital, Datta Meghe Institute of Higher Education and Research (Deemed to be University), Wardha, Maharashtra, India
2 shared publications - Pranjali Vilas Deulkar
Pediatric and Preventive Dentistry, Dr. D. Y. Patil Dental college and Hospital, Dr D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, 411018
2 shared publications - Sphurti P. Bane
Pediatric and Preventive Dentistry, Private Practitioner, Mumbai, IND
2 shared publications Sudhindra Baliga
Department of Pediatric and Preventive Dentistry Sharad Pawar Dental College Datta Meghe Institute of Medical Sciences Wardha Maharashtra India
2 shared publications
Latest Publications
- Open Access
- 20 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28207
Comparative Evaluation of Antibacterial Efficacy of Emblica Officinalis Lollipop Against Streptococcus Mutans Counts in Institutionalized Visually Impaired Children
Among the 1.21 billion population of India, 26.8 million individuals have disabilities, and around five million are visually impaired. These children encounter problems related to oral health maintenance, thus further leading to dental problems. Even though Pediatric dentists treat visually impaired children for their oral problems, they emphasize mainly on the prevention of dental caries. Dental caries has a multifactorial etiology, and dentists are unable to find a complete solution for its prevention. However, reducing Streptococcus mutans has been seen to reduce the caries rate in the past. The use of the herbal product Emblica officinalis to reduce Streptococcus mutans levels has been documented. An affordable delivery system is required to use Emblica officinalis for its anticaries action. Thus, a unique delivery system of herbal sugar-free lollipops containing Emblica officinalis extract was made and can effectively deliver antimicrobial action in visually impaired children. To evaluate the antibacterial efficacy of Emblica officinalis lollipop on Streptococcus mutans counts and pH levels in institutionalized visually impaired children. A total of 60 institutionalized visually impaired children (age: 4 to 14 years) were selected. The study consisted of two groups (experimental “Emblica officinalis lollipop” and control “placebo lollipop”), and the children were divided equally into both groups. Children from the study and control groups were subjected to the respective lollipops twice daily for seven days. Streptococcus mutans count and pH count were evaluated at baseline and after seven days post-intervention of the respective lollipop. The results showed that in both groups, Streptococcus mutans count was reduced post-intervention. However, the efficacy of the study group (Emblica officinalis lollipop) in inhibiting the Streptococcus mutans count was better than the control group (placebo lollipop). An increase in the pH level was seen post-intervention for both the study and control groups. And on the intergroup comparison, no statistical significance was found. The use of Emblica officinalis lollipop is effective in inhibiting the Streptococcus mutans count when compared with the placebo lollipop. While marginal pH change was seen in both groups. Thus, the herbal modality most acceptable without any pharmaceutical concerns should be chosen. Emblica officinalis lollipops can be used in institutionalized visually impaired children to reduce the oral Streptococcus mutans count and maintain a healthy oral cavity.
- 20 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28207
Open AccessComparative Evaluation of Antibacterial Efficacy of Emblica Officinalis Lollipop Against Streptococcus Mutans Counts in Institutionalized Visually Impaired Children
Among the 1.21 billion population of India, 26.8 million individuals have disabilities, and around five million are visually impaired. These children encounter problems related to oral health maintenance, thus further leading to dental problems. Even though Pediatric dentists treat visually impaired children for their oral problems, they emphasize mainly on the prevention of dental caries. Dental caries has a multifactorial etiology, and dentists are unable to find a complete solution for its prevention. However, reducing Streptococcus mutans has been seen to reduce the caries rate in the past. The use of the herbal product Emblica officinalis to reduce Streptococcus mutans levels has been documented. An affordable delivery system is required to use Emblica officinalis for its anticaries action. Thus, a unique delivery system of herbal sugar-free lollipops containing Emblica officinalis extract was made and can effectively deliver antimicrobial action in visually impaired children. To evaluate the antibacterial efficacy of Emblica officinalis lollipop on Streptococcus mutans counts and pH levels in institutionalized visually impaired children. A total of 60 institutionalized visually impaired children (age: 4 to 14 years) were selected. The study consisted of two groups (experimental “Emblica officinalis lollipop” and control “placebo lollipop”), and the children were divided equally into both groups. Children from the study and control groups were subjected to the respective lollipops twice daily for seven days. Streptococcus mutans count and pH count were evaluated at baseline and after seven days post-intervention of the respective lollipop. The results showed that in both groups, Streptococcus mutans count was reduced post-intervention. However, the efficacy of the study group (Emblica officinalis lollipop) in inhibiting the Streptococcus mutans count was better than the control group (placebo lollipop). An increase in the pH level was seen post-intervention for both the study and control groups. And on the intergroup comparison, no statistical significance was found. The use of Emblica officinalis lollipop is effective in inhibiting the Streptococcus mutans count when compared with the placebo lollipop. While marginal pH change was seen in both groups. Thus, the herbal modality most acceptable without any pharmaceutical concerns should be chosen. Emblica officinalis lollipops can be used in institutionalized visually impaired children to reduce the oral Streptococcus mutans count and maintain a healthy oral cavity.
- Open Access
- 18 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28141
Effectiveness of Two Different Behavior Modification Techniques for Anxiety Reduction in Children
Dental anxiety has been a major concern for dentists while operating children. For a smooth, uneventful treatment, operators must incorporate various behavior management techniques in their practice. The incorporation of magic tricks as behavior management techniques has been used earlier by physicians and nurses to reduce pre-operative anxiety in hospitals. This study aimed to compare the impacts of magic tricks on reducing dental anxiety in children. Patients aged four to 11 years were eligible for inclusion. The study comprised two groups of 15 children each. During the first visit, children weren’t subjected to any behavior management. Behavior management aids (magic tricks and audiovisuals) were used during the second visit. Hemodynamic parameters along with an anxiety scale were used to assess anxiety in children before, during, and after treatment procedures. Venham’s picture test and modified visual analog scale were also used to assess the anxiety. A reduction in anxiety was seen in both groups after behavior management was used. The hemodynamic parameters like blood pressure and pulse rate were seen to decrease during the second visit, while the oxygen saturation was seen to increase. The study demonstrates that magic trick along with audiovisual aids was effective in controlling dental anxiety. Thus, magic tricks can be used in dental practice as a behavior management aid for children to facilitate cooperative behavior. Reducing a child's dental anxiety through various different magic trick aids could be a potential behavior management modality that needs further research.
- 18 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28141
Open AccessEffectiveness of Two Different Behavior Modification Techniques for Anxiety Reduction in Children
Dental anxiety has been a major concern for dentists while operating children. For a smooth, uneventful treatment, operators must incorporate various behavior management techniques in their practice. The incorporation of magic tricks as behavior management techniques has been used earlier by physicians and nurses to reduce pre-operative anxiety in hospitals. This study aimed to compare the impacts of magic tricks on reducing dental anxiety in children. Patients aged four to 11 years were eligible for inclusion. The study comprised two groups of 15 children each. During the first visit, children weren’t subjected to any behavior management. Behavior management aids (magic tricks and audiovisuals) were used during the second visit. Hemodynamic parameters along with an anxiety scale were used to assess anxiety in children before, during, and after treatment procedures. Venham’s picture test and modified visual analog scale were also used to assess the anxiety. A reduction in anxiety was seen in both groups after behavior management was used. The hemodynamic parameters like blood pressure and pulse rate were seen to decrease during the second visit, while the oxygen saturation was seen to increase. The study demonstrates that magic trick along with audiovisual aids was effective in controlling dental anxiety. Thus, magic tricks can be used in dental practice as a behavior management aid for children to facilitate cooperative behavior. Reducing a child's dental anxiety through various different magic trick aids could be a potential behavior management modality that needs further research.
- 14 April 2021
- Published by Wiley in Special Care in Dentistry
- Vol. 41 (5) , 619-625
Evaluation of antibacterial efficacy of Triphala toothwipes on oral Streptococcus mutans count in intellectually disabled children
Aim: To evaluate antibacterial efficacy of Triphala toothwipes on oral Streptococcus mutans counts in intellectually disabled (ID) children.Methods: Twenty‐seven children with a mild ID were randomly divided into two groups: A ‐ Triphala and B ‐ placebo group. Toothwipes were given to caregivers of children belonging to the respective groups, and were instructed to use them 1 h after their meals, twice a day for 7 days. Simplified Plaque index was recorded and plaque samples were collected for microbiological examination at baseline, 48 h, and 7 days. The obtained data were tabulated and analyzed.Results: Triphala group showed a statistically significant reduction of S. mutans after 48 h and 7 days. Both Triphala and placebo groups showed a statistically significant reduction in dental plaque after 48 h and 7 days.Conclusion: Triphala toothwipes are effective against the oral S. mutans compared with placebo toothwipes, while both the toothwipes are equally effective in reducing dental plaque. Thus, Triphala toothwipes can be used as an adjunct aid along with routine oral hygiene practices in individuals who lack psychomotor skills or are dependent on others to maintain oral hygiene, including infants, preschoolers, geriatric population, and children with special health care needs.
- 14 April 2021
- Published by Wiley in Special Care in Dentistry
- Vol. 41 (5) , 619-625
Evaluation of antibacterial efficacy of Triphala toothwipes on oral Streptococcus mutans count in intellectually disabled children
Aim: To evaluate antibacterial efficacy of Triphala toothwipes on oral Streptococcus mutans counts in intellectually disabled (ID) children.Methods: Twenty‐seven children with a mild ID were randomly divided into two groups: A ‐ Triphala and B ‐ placebo group. Toothwipes were given to caregivers of children belonging to the respective groups, and were instructed to use them 1 h after their meals, twice a day for 7 days. Simplified Plaque index was recorded and plaque samples were collected for microbiological examination at baseline, 48 h, and 7 days. The obtained data were tabulated and analyzed.Results: Triphala group showed a statistically significant reduction of S. mutans after 48 h and 7 days. Both Triphala and placebo groups showed a statistically significant reduction in dental plaque after 48 h and 7 days.Conclusion: Triphala toothwipes are effective against the oral S. mutans compared with placebo toothwipes, while both the toothwipes are equally effective in reducing dental plaque. Thus, Triphala toothwipes can be used as an adjunct aid along with routine oral hygiene practices in individuals who lack psychomotor skills or are dependent on others to maintain oral hygiene, including infants, preschoolers, geriatric population, and children with special health care needs.
- 24 August 2020
- Published by Akshantala Enterprises Private Limited in Journal of Evolution of Medical and Dental Sciences
- Vol. 9 (34) , 2479-2483
Probiotic Bacteriotherapy and Its Oral Health Perspective
- 24 August 2020
- Published by Akshantala Enterprises Private Limited in Journal of Evolution of Medical and Dental Sciences
- Vol. 9 (34) , 2479-2483
Probiotic Bacteriotherapy and Its Oral Health Perspective
- Open Access
- 19 November 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (21) , 2517
Impact Assessment of Immunogenicity of Romiplostim In Subjects with Immune Thrombocytopenic Purpura (ITP)
Abstract 2517 Romiplostim is a peptibody that increases platelet production via binding to the thrombopoietin (TPO) receptor. This molecule has been engineered to have no amino acid sequence homology to endogenous TPO (eTPO); however, a low theoretical risk of developing conformational antibodies that cross-react with eTPO does exist. The current immunogenicity assessment strategy detects antibodies that bind to romiplostim, TPO, or TMP (the active peptide portion of romiplostim) and identifies any antibodies capable of neutralizing the biological effect of the drug or TPO. In clinical studies, 537 subjects with ITP were dosed with romiplostim; 31 (5.8%) subjects developed binding antibodies to romiplostim and 21 (3.9%) subjects developed binding antibodies to TPO. However, only 2 (0.4%) of these subjects had antibodies that neutralized the biological effect of romiplostim. The binding antibodies detected against romiplostim were not cross-reactive with TPO in the immunoassay and did not neutralize TPO in the biological assay. Pre-existing binding antibodies against romiplostim were detected in 43 (8.0%) subjects and against TPO in 29 (5.4%) subjects. The immunogenicity rates in Japanese ITP subjects (n=46) dosed with romiplostim were comparable to non-Japanese subjects. As a part of the post-marketing risk management strategy, Amgen performed immunogenicity testing on 37 subjects. Of these subjects, 3 developed binding antibodies against romiplostim that were not cross-reactive with TPO. None of these subjects developed neutralizing antibodies to romiplostim or TPO. The impact of immunogenicity to romiplostim on safety and efficacy was evaluated utilizing platelet profile as a pharmacodynamic marker. No significant impact of the antibodies against romiplostim and TPO on the development of adverse events was noted. Grade 3 and above hypersensitivity related events were found in subjects that were antibody-positive and antibody-negative in the same proportion, indicating that these events were not related to anti-romiplostim or anti-TPO antibodies. No clinical correlation could be made between the development of antibodies against romiplostim and/or against TPO and the previous drug therapies or concomitant medications. No correlation between binding antibodies to romiplostim or TPO and platelet profiles of these subjects could be established. The subjects that developed a neutralizing antibody response against romiplostim were associated with a trend of lower platelet counts. The reduced platelet counts could be attributed to the presence of binding and neutralizing antibodies to romiplostim. Alternatively, the lowering of the platelet counts could also be attributed to discontinuation of therapy at the end of study.
- 19 November 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (21) , 2517
Open AccessImpact Assessment of Immunogenicity of Romiplostim In Subjects with Immune Thrombocytopenic Purpura (ITP)
Abstract 2517 Romiplostim is a peptibody that increases platelet production via binding to the thrombopoietin (TPO) receptor. This molecule has been engineered to have no amino acid sequence homology to endogenous TPO (eTPO); however, a low theoretical risk of developing conformational antibodies that cross-react with eTPO does exist. The current immunogenicity assessment strategy detects antibodies that bind to romiplostim, TPO, or TMP (the active peptide portion of romiplostim) and identifies any antibodies capable of neutralizing the biological effect of the drug or TPO. In clinical studies, 537 subjects with ITP were dosed with romiplostim; 31 (5.8%) subjects developed binding antibodies to romiplostim and 21 (3.9%) subjects developed binding antibodies to TPO. However, only 2 (0.4%) of these subjects had antibodies that neutralized the biological effect of romiplostim. The binding antibodies detected against romiplostim were not cross-reactive with TPO in the immunoassay and did not neutralize TPO in the biological assay. Pre-existing binding antibodies against romiplostim were detected in 43 (8.0%) subjects and against TPO in 29 (5.4%) subjects. The immunogenicity rates in Japanese ITP subjects (n=46) dosed with romiplostim were comparable to non-Japanese subjects. As a part of the post-marketing risk management strategy, Amgen performed immunogenicity testing on 37 subjects. Of these subjects, 3 developed binding antibodies against romiplostim that were not cross-reactive with TPO. None of these subjects developed neutralizing antibodies to romiplostim or TPO. The impact of immunogenicity to romiplostim on safety and efficacy was evaluated utilizing platelet profile as a pharmacodynamic marker. No significant impact of the antibodies against romiplostim and TPO on the development of adverse events was noted. Grade 3 and above hypersensitivity related events were found in subjects that were antibody-positive and antibody-negative in the same proportion, indicating that these events were not related to anti-romiplostim or anti-TPO antibodies. No clinical correlation could be made between the development of antibodies against romiplostim and/or against TPO and the previous drug therapies or concomitant medications. No correlation between binding antibodies to romiplostim or TPO and platelet profiles of these subjects could be established. The subjects that developed a neutralizing antibody response against romiplostim were associated with a trend of lower platelet counts. The reduced platelet counts could be attributed to the presence of binding and neutralizing antibodies to romiplostim. Alternatively, the lowering of the platelet counts could also be attributed to discontinuation of therapy at the end of study.